TBPH
Theravance BiopharmaDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-20
Current thesis
The post-earnings bull case is that Q1 results reinforced the non-pipeline value floor: quarter-end cash was about $395 million with no debt, Q1 net loss narrowed materially year over year to $4.9 million from $13.6 million, YUPELRI trends stayed positive, and management reiterated confidence in the 2026 TRELEGY milestone path [#8-K-2026-05-07] [#10-Q-2026-05-07].
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.0.
What can break
Management's $60-$70 million annualized cash-flow goal depends on delivering the planned restructuring and sustaining lower operating expenses into Q3 2026 and beyond [#8-K-2026-05-07].
Momentum
30
Value
57
Sentiment
46
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $17.00 · Bull $22.00 · Bear $13.00
Data freshness
Prices
As of 2026-07-20
Fundamentals
As of 2026-07-21 • Vendor: Data Vendor v1
Scores
As of 2026-07-20 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-08 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-20
Investment thesis
As of 2026-07-20
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $17.67
Why
Momentum30 · Δ7d -4.9
Value57 · Δ7d -0.0
Sentiment46 · Δ7d -3.6
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Value · See fundamentals
Momentum
30
26% active weight
Current posture
7d trendFlat
Δ7d
-4.9
Δ21d
-30.1
Value
57
39% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.1
Sentiment
46
34% active weight
Current posture
7d trendSoftening
Δ7d
-3.6
Δ21d
+2.1
Why this grade
Composite grade D. Momentum 30.3 / Value 56.8 / Sentiment 46.0
Fundamentals (TTM)As of 2026-07-21
Fundamentals (TTM)
As of 2026-07-21
Market Cap
$872.79M
Beta
0.15
Shares Out
51.83M
P/E (TTM)
32.7
P/S (TTM)
11.62
P/FCF (TTM)
3.83
Rev YoY
+15.0%
EPS YoY
-64.8%
Gross Margin
+94.8%
Op Margin
-40.9%
Net Debt
-$239.86M
Current Ratio
13.14
As of 2026-07-20 • Updated nightlySource: Internal modelMethodology